ESTRO 2024 - Abstract Book

S1603

Clinical - Lung

ESTRO 2024

Results:

Seventy five patients were randomized between January 2021, and January 2023. Of 75 patients, 38 patients were assigned to the control arm and 37 patients to the consolidative radiotherapy arm. Median follow-up was 13.50 months (4.50 – 35.93). Median PFS was 15.37 months in the radiotherapy group versus 10.93 months in the control group (hazard ratio 1.99, 95% CI 1.16-3.41; p=0.012). Median overall survival was 18.30 months in the radiotherapy group versus 13.73 months in the control group (hazard ratio 1.84, 95% CI 0.98-3.46; p=0.057). toxicity of grades 1 and 2 weren’t significantly different between arms except for chest wall pain; 21% of radiotherapy arm suffered one grade deterioration vs no body in the control arm p= 0.005. Only one patient developed grade 3 dysphagia in the radiotherapy group vs non in the control arm and no treatment-related deaths.

Conclusion:

Radical radiotherapy to the primary lesion only in metastatic NSCLC after response on systemic treatment can be a good alternative option for metastatic NSCLC patients especially those with expected more toxicity from SBRT due to the distant metastasis’s location or their number also for poor countries lacking SBRT modality in most of their radiation centers.

Keywords: Advanced lung cancer, radiotherapy, Primary

377

Digital Poster

ESR/ATS Thresholds for DL CO Correlate with Radiation Dosimetry and Pneumonitis Rate in NSCLC III

Elvis Ruznic 1 , Markus Stana 1 , Brane Grambozov 1 , Josef Karner 1 , Isabella Gollner 1 , Christoph Gaisberger 1 , Barbara Zellinger 2 , Raphaela Moosbrugger 3 , Michael Studnicka 3 , Gerd Fastner 1 , Felix Sedlmayer 1 , Franz Zehentmayr 1 1 Paracelsus Medical University, Department of Radiation Oncology, Salzburg, Austria. 2 Paracelsus Medical University, Institute of Pathology, Salzburg, Austria. 3 Paracelsus Medical University, Department of Pulmonology, Salzburg, Austria

Purpose/Objective:

Durvalumab following chemoradiotherapy (CRT) for non-small cell lung cancer stage III has become the standard of care (SoC) in the past few years. With this regimen, 5-year overall survival (OS) has risen to 43%. Therefore, adequate pulmonary function (PF) after treatment is paramount in long-term survivors. In this respect, carbon monoxide diffusing capacity (DL CO ), which represents the alveolar compartment, is a suitable measure for residual lung capacity. The aim of the current analysis was to correlate DL CO with pneumonitis and radiation dose.

Material/Methods: